Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Income from Continuing Operations (2021 - 2025)

Historic Income from Continuing Operations for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to -$12.1 million.

  • SAB Biotherapeutics' Income from Continuing Operations fell 1659.63% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.6 million, marking a year-over-year increase of 657.27%. This contributed to the annual value of -$41.9 million for FY2024, which is 59.45% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Income from Continuing Operations stood at -$12.1 million for Q3 2025, which was down 1659.63% from -$9.8 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Income from Continuing Operations high stood at $1.4 million for Q1 2021, and its period low was -$22.9 million during Q4 2023.
  • Over the past 5 years, SAB Biotherapeutics' median Income from Continuing Operations value was -$7.3 million (recorded in 2024), while the average stood at -$7.5 million.
  • In the last 5 years, SAB Biotherapeutics' Income from Continuing Operations plummeted by 84592.72% in 2023 and then skyrocketed by 5649.72% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Income from Continuing Operations (Quarter) stood at -$11.6 million in 2021, then soared by 32.05% to -$7.8 million in 2022, then crashed by 191.21% to -$22.9 million in 2023, then skyrocketed by 56.5% to -$9.9 million in 2024, then decreased by 21.36% to -$12.1 million in 2025.
  • Its Income from Continuing Operations was -$12.1 million in Q3 2025, compared to -$9.8 million in Q2 2025 and -$10.8 million in Q1 2025.